

# Minoli A Perera

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2943764/publications.pdf>

Version: 2024-02-01

41  
papers

1,667  
citations

471061

17  
h-index

377514

34  
g-index

46  
all docs

46  
docs citations

46  
times ranked

2348  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogeneticsâ€Guided Warfarin Dosing: 2017 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 397-404.	2.3	479
2	Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. <i>Lancet, The</i> , 2013, 382, 790-796.	6.3	237
3	Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 778-786.	2.3	110
4	The Missing Association: Sequencing-Based Discovery of Novel SNPs in VKORC1 and CYP2C9 That Affect Warfarin Dose in African Americans. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 408-415.	2.3	100
5	Effect of <i>NQO1</i> and <i>CYP4F2</i> genotypes on warfarin dose requirements in Hispanicâ€Americans and Africanâ€Americans. <i>Pharmacogenomics</i> , 2012, 13, 1925-1935.	0.6	59
6	Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans. <i>Pharmacogenomics Journal</i> , 2014, 14, 223-228.	0.9	59
7	Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. <i>Blood</i> , 2014, 124, 2298-2305.	0.6	57
8	The future of warfarin pharmacogenetics in under-represented minority groups. <i>Future Cardiology</i> , 2012, 8, 563-576.	0.5	56
9	Pharmacogenetic Testing for Uridine Diphosphate Glucuronosyltransferase 1A1 Polymorphisms: Are We There Yet?. <i>Pharmacotherapy</i> , 2008, 28, 755-768.	1.2	52
10	On Using Local Ancestry to Characterize the Genetic Architecture of Human Traits: Genetic Regulation of Gene Expression in Multiethnic or Admixed Populations. <i>American Journal of Human Genetics</i> , 2019, 104, 1097-1115.	2.6	50
11	Genetic Factors Influencing Warfarin Dose in Blackâ€African Patients: A Systematic Review and Metaâ€Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1420-1433.	2.3	40
12	A Review of African Americansâ€™ Beliefs and Attitudes About Genomic Studies: Opportunities for Message Design. <i>Frontiers in Genetics</i> , 2019, 10, 548.	1.1	39
13	The missing linkage: what pharmacogenetic associations are left to find in <i>CYP3A</i> ? <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 17-28.	1.5	38
14	Novel genetic predictors of venous thromboembolism risk in African Americans. <i>Blood</i> , 2016, 127, 1923-1929.	0.6	38
15	The ACCO-NT Consortium: A Model for the Discovery, Translation, and Implementation of Precision Medicine in African Americans. <i>Clinical and Translational Science</i> , 2019, 12, 209-217.	1.5	32
16	The Advantages and Challenges of Diversity in Pharmacogenomics: Can Minority Populations Bring Us Closer to Implementation?. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 338-349.	2.3	31
17	Association of Genetic Variants With Warfarin-Associated Bleeding Among Patients of African Descent. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1670.	3.8	25
18	Discovery of novel hepatocyte eQTLs in African Americans. <i>PLoS Genetics</i> , 2020, 16, e1008662.	1.5	21

#	ARTICLE	IF	CITATIONS
19	Cardiovascular Pharmacogenomics: Does It Matter If You're Black or White?. Annual Review of Pharmacology and Toxicology, 2019, 59, 577-603.	4.2	19
20	Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms. Pharmacogenomics Journal, 2017, 17, 494-500.	0.9	16
21	Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms. Pharmacogenomics, 2015, 16, 217-225.	0.6	14
22	Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation. Pharmacogenomics Journal, 2020, 20, 126-135.	0.9	14
23	Impact of CYP2C9-Interacting Drugs on Warfarin Pharmacogenomics. Clinical and Translational Science, 2020, 13, 941-949.	1.5	13
24	Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations. Clinical Pharmacokinetics, 2019, 58, 1077-1089.	1.6	12
25	Why African Americans Say "No": A Study of Pharmacogenomic Research Participation. Ethnicity and Disease, 2020, 30, 159-166.	1.0	9
26	Hepatocyte gene expression and DNA methylation as ancestry-dependent mechanisms in African Americans. Npj Genomic Medicine, 2019, 4, 29.	1.7	8
27	Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes. Pharmacogenomics Journal, 2018, 18, 106-112.	0.9	7
28	Warfarin Dosing in Patients With <i>CYP2C9*5</i> Variant Alleles. Clinical Pharmacology and Therapeutics, 2022, 111, 950-955.	2.3	7
29	Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans. Translational Research, 2015, 165, 651-657.	2.2	6
30	Differences in the Platelet mRNA Landscape Portend Racial Disparities in Platelet Function and Suggest Novel Therapeutic Targets. Clinical Pharmacology and Therapeutics, 2021, 110, 702-713.	2.3	5
31	Leaving some behind: the growing gap in precision medicine for minority populations. Expert Review of Precision Medicine and Drug Development, 2019, 4, 3-5.	0.4	4
32	Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans. Journal of Thrombosis and Haemostasis, 2017, 15, 735-743.	1.9	3
33	Genetic association of primary nonresponse to anti-TNF± therapy in patients with inflammatory bowel disease. Pharmacogenetics and Genomics, 2022, 32, 1-9.	0.7	2
34	Applicability of Pharmacogenomically Guided Medication Treatment during Hospitalization of At-Risk Minority Patients. Journal of Personalized Medicine, 2021, 11, 1343.	1.1	2
35	Incorporation of DNA methylation into eQTL mapping in African Americans. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2021, 26, 244-255.	0.7	0
36	GPCR Patient Drug Interaction"Pharmacogenetics: Genome-Wide Association Studies (GWAS). , 2021, , .		0

#	ARTICLE	IF	CITATIONS
37	Incorporation of DNA methylation into eQTL mapping in African Americans. , 2020, , .		0
38	Discovery of novel hepatocyte eQTLs in African Americans. , 2020, 16, e1008662.		0
39	Discovery of novel hepatocyte eQTLs in African Americans. , 2020, 16, e1008662.		0
40	Discovery of novel hepatocyte eQTLs in African Americans. , 2020, 16, e1008662.		0
41	Discovery of novel hepatocyte eQTLs in African Americans. , 2020, 16, e1008662.		0